Links between mutant p53 and genomic instability

Journal of Cellular Biochemistry

Volumn 113, Issue 2, 2012, Pages 433-439

  Hanel, Walter ^a   Moll, Ute M ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Aneuploidy; DNA damage checkpoint; Genomic instability; Mutant p53; Spindle assembly checkpoint; Translocations

Indexed keywords

ANAPHASE PROMOTING COMPLEX; DNA; DNA TOPOISOMERASE; PROTEIN P53; PROTEIN P63; PROTEIN P73; T LYMPHOCYTE RECEPTOR;

ANEUPLOIDY; APOPTOSIS; BREAST TUMOR; CARCINOGENESIS; CELL DEATH; CELL VIABILITY; CENTROSOME; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CHROMOSOME STRUCTURE; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; FIBROBLAST; GENE AMPLIFICATION; GENE EXPRESSION; GENE FREQUENCY; GENE INACTIVATION; GENETIC VARIABILITY; GENOMIC INSTABILITY; HUMAN; LOSS OF FUNCTION MUTATION; M PHASE CELL CYCLE CHECKPOINT; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; TELOMERE; TUMOR CELL; TUMOR SUPPRESSOR GENE; WILD TYPE;

ANEUPLOIDY; ANIMALS; CELL SURVIVAL; DNA DAMAGE; GENE AMPLIFICATION; GENOMIC INSTABILITY; HUMANS; MUTATION; NEOPLASMS; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855551714     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23400     Document Type: Review

References (70)

1. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, Parenti AR, Rosato A, Bicciato S, Balmain A, Piccolo S. 2009. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137:87-98.
2. Andreassen PR, Lohez OD, Lacroix FB, Margolis RL. 2001. Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol Biol Cell 12:1315-1328. (Pubitemid 33044413)
3. Ashwell S, Zabludoff S. 2008. DNA damage detection and repair pathways - Recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 14:4032-4037.
4. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, Hamilton S, Vogelstein B. 1990. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50:7717-7722.
5. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T. 2003. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3:387-402. (Pubitemid 38340307)
6. Blandino G, Levine AJ, Oren M. 1999. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18:477-485. (Pubitemid 29060623)
7. Borden EC, Baker LH, Bell RS, Bramwell V, Demetri GD, Eisenberg BL, Fletcher CD, Fletcher JA, Ladanyi M, Meltzer P, O'Sullivan B, Parkinson DR, Pisters PW, Saxman S, Singer S, Sundaram M, van Oosterom AT, Verweij J, Waalen J, Weiss SW, Brennan MF. 2003. Soft tissue sarcomas of adults: State of the translational science. Clin Cancer Res 9:1941-1956. (Pubitemid 36687613)
8. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. 2006. Mutant p53 gain of function: Reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 25:304-309. (Pubitemid 43083692)
9. Brosh R, Rotter V. 2009. When mutants gain new powers: News from the mutant p53 field. Nat Rev 9:701-713.
10. Buis J, Wu Y, Deng Y, Leddon J, Westfield G, Eckersdorff M, Sekiguchi JM, Chang S, Ferguson DO. 2008. Mre11 nuclease activity has essential roles in DNA repair and genomic stability distinct from ATM activation. Cell 135:85-96.
11. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik- Zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Griffin CA, Burton J, Swerdlow H, Quail MA, Stratton MR, Iacobuzio-Donahue C, Futreal PA. 2010. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467:1109-1113.
12. Carroll PE, Okuda M, Horn HF, Biddinger P, Stambrook PJ, Gleich LL, Li YQ, Tarapore P, Fukasawa K. 1999. Centrosome hyperamplification in human cancer: Chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 18:1935-1944. (Pubitemid 29150080)
13. Caulin C, Nguyen T, Lang GA, Goepfert TM, Brinkley BR, Cai WW, Lozano G, Roop DR. 2007. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest 117:1893-1901. (Pubitemid 47036323)
14. de Lange T. 2002. Protection ofmammalian telomeres. Oncogene 21:532-540.
15. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, Blandino G, Piaggio G. 2006. Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10:191-202. (Pubitemid 44311070)
16. Doyle B, Morton JP, Delaney DW, Ridgway RA, Wilkins JA, Sansom OJ. 2010. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J Pathol 222:129-137.
17. El-Hizawi S, Lagowski JP, Kulesz-MartinM, Albor A. 2002. Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins. Cancer Res 62:3264-3270. (Pubitemid 34602423)
18. Essers J, van Steeg H, de Wit J, Swagemakers SM, Vermeij M, Hoeijmakers JH, Kanaar R. 2000. Homologous and non-homologous recombination differentially affect DNA damage repair in mice. EMBO J 19:1703-1710. (Pubitemid 30182176)
19. Fedier A, Schlamminger M, Schwarz VA, Haller U, Howell SB, Fink D. 2003. Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. Ann Oncol 14:938-945. (Pubitemid 36827211)
20. Gaiddon C, Lokshin M, Gross I, Levasseur D, Taya Y, Loeffler JP, Prives C. 2003. Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73. J Biol Chem 278:27421-27431. (Pubitemid 36899924)
21. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A, Mano M, Rosato A, Crook T, Scanziani E, Means AR, Lozano G, Schneider C, Del Sal G. 2011. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 20:79-91.
22. Gobert C, Skladanowski A, Larsen AK. 1999. The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53. Proc Natl Acad Sci USA 96:10355-10360. (Pubitemid 29422562)
23. Gualberto A, Aldape K, Kozakiewicz K, Tlsty TD. 1998. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci USA 95:5166-5171. (Pubitemid 28208569)
24. Guinn BA, Padua RA, Burnett A, Mills K. 1994. p53 mutations indicate a changing clonal evolution in a portion of chronic myelocytic leukemia patients. Blood 84:3591. (Pubitemid 24352927)
25. Ha GH, Baek KH, Kim HS, Jeong SJ, Kim CM, McKeon F, Lee CW. 2007. p53 activation in response to mitotic spindle damage requires signaling via BubR1-mediated phosphorylation. Cancer Res 67:7155-7164. (Pubitemid 47206543)
26. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. 2005. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469-483. (Pubitemid 40719130)
27. Hruban RH, Goggins M, Parsons J, Kern SE. 2000. Progression model for pancreatic cancer. Clin Cancer Res 6:2969-2972. (Pubitemid 30637716)
28. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG, Jr. 2003. Chemosensitivity linked to p73 function. Cancer Cell 3:403-410. (Pubitemid 38340308)
29. Iwamoto KS, Mizuno T, Ito T, Tsuyama N, Kyoizumi S, Seyama T. 1996. Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival. Cancer Res 56:3862-3865. (Pubitemid 26284727)
30. Jackson SP. 2002. Sensing and repairing DNA double-strand breaks. Carcinogenesis 23:687-696. (Pubitemid 34567505)
31. Jain AN, Chin K, Borresen-Dale AL, Erikstein BK, Eynstein Lonning P, Kaaresen R, Gray JW. 2001. Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proc Natl Acad Sci USA 98:7952-7957. (Pubitemid 32642668)
32. Jong YJ, Li LH, Tsou MH, Chen YJ, Cheng SH, Wang-Wuu S, Tsai SF, Chen CM, Huang AT, Hsu MT, Lin CH. 2004. Chromosomal comparative genomic hybridization abnormalities in early- and late-onset human breast cancers: Correlation with disease progression and TP53 mutations. Cancer Genet Cytogenet 148:55-65. (Pubitemid 38018881)
33. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819. (Pubitemid 27357971)
34. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119:861-872. (Pubitemid 40017691)
35. Lanni JS, Jacks T. 1998. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 18:1055-1064. (Pubitemid 28063440)
36. Lengauer C, Kinzler KW, Vogelstein B. 1998. Genetic instabilities in human cancers. Nature 396:643-649. (Pubitemid 29003936)
37. Li Y, Prives C. 2007. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 26:2220-2225. (Pubitemid 46536648)
38. Li B, Murphy KL, Laucirica R, Kittrell F, Medina D, Rosen JM. 1998. A transgenic mouse model for mammary carcinogenesis. Oncogene 16:997-1007. (Pubitemid 28107938)
39. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. 1992. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935.
40. Lokshin M, Tanaka T, Prives C. 2005. Transcriptional regulation by p53 and p73. Cold Spring Harb Symp Quant Biol 70:121-128. (Pubitemid 44124863)
41. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P, Cromer A, Brugge JS, Sansom OJ, Norman JC, Vousden KH. 2009. Mutant p53 drives invasion by promoting integrin recycling. Cell 139:1327-1341.
42. Muller PA, Vousden KH, Norman JC. 2011. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192:209-218.
43. Murphy KL, Dennis AP, Rosen JM. 2000. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J 14:2291-2302.
44. Oikawa T, Okuda M, Ma Z, Goorha R, Tsujimoto H, Inokuma H, Fukasawa K. 2005. Transcriptional control of BubR1 by p53 and suppression of centrosome amplification by BubR1. Mol Cell Biol 25:4046-4061. (Pubitemid 40617653)
45. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119:847-860. (Pubitemid 40017690)
46. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Borresen-Dale AL. 2006. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12:1157-1167. (Pubitemid 43342504)
47. Overholtzer M, Rao PH, Favis R, Lu XY, Elowitz MB, Barany F, Ladanyi M, Gorlick R, Levine AJ. 2003. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci USA 100:11547-11552. (Pubitemid 37205973)
48. Rufini A, Agostini M, Grespi F, Tomasini R, Sayan BS, Niklison-Chirou MV, Conforti F, Velletri T, Mastino A, Mak TW, Melino G, Knight RA. 2011. p73 in cancer. Genes Cancer 2:491-502.
49. Schilling T, Kairat A, Melino G, Krammer PH, Stremmel W, Oren M, Muller M. 2010. Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma. Biochem Biophys Res Commun 394:817-823.
50. Sigal A, Rotter V. 2000. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res 60:6788-6793. (Pubitemid 32059139)
51. Smogorzewska A, Karlseder J, Holtgreve-Grez H, Jauch A, de Lange T. 2002. DNA ligase IV-dependent NHEJ of deprotected mammalian telomeres in G1 and G2. Curr Biol 12:1635-1644. (Pubitemid 35161916)
52. Song H, Hollstein M, Xu Y. 2007. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 9:573-580. (Pubitemid 46696539)
53. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, Leung ML, El-Naggar A, Creighton CJ, Suraokar MB, Wistuba I, Flores ER. 2010. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 467:986-990.
54. Takata M, Sasaki MS, Sonoda E, Morrison C, Hashimoto M, Utsumi H, Yamaguchi-Iwai Y, Shinohara A, Takeda S. 1998. Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 17:5497-5508. (Pubitemid 28427063)
55. Tarapore P, Fukasawa K. 2002. Loss of p53 and centrosome hyperamplification. Oncogene 21:6234-6240.
56. Tarapore P, Tokuyama Y, Horn HF, Fukasawa K. 2001. Difference in the centrosome duplication regulatory activity among p53 'hot spot' mutants: Potential role of Ser 315 phosphorylation-dependent centrosome binding of p53. Oncogene 20:6851-6863. (Pubitemid 33052175)
57. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC, Khan F, Itie-Youten A, Wakeham A, Tsao MS, Iovanna JL, Squire J, Jurisica I, Kaplan D, Melino G, Jurisicova A, Mak TW. 2008. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 22:2677-2691.
58. Tomasini R, Tsuchihara K, Tsuda C, Lau SK, Wilhelm M, Ruffini A, Tsao MS, Iovanna JL, Jurisicova A, Melino G, Mak TW. 2009. TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. Proc Natl Acad Sci USA 106:797-802.
59. Tutt A, Connor F, Bertwistle D, Kerr P, Peacock J, Ross G, Ashworth A. 2003. Cell cycle and genetic background dependence of the effect of loss of BRCA2 on ionizing radiation sensitivity. Oncogene 22:2926-2931. (Pubitemid 36648919)
60. Urist M, Tanaka T, Poyurovsky MV, Prives C. 2004. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev 18:3041-3054. (Pubitemid 39658173)
61. Vaseva AV, Moll UM. 2009. The mitochondrial p53 pathway. Biochim Biophys Acta 1787:414-420.
62. Wang XJ, Greenhalgh DA, Jiang A, He D, Zhong L, Brinkley BR, Roop DR. 1998. Analysis of centrosome abnormalities and angiogenesis in epidermal-targeted p53172H mutant and p53-knockout mice after chemical carcinogenesis: Evidence for a gain of function. Mol Carcinog 23:185-192. (Pubitemid 28535822)
63. Weber RG, Bridger JM, Benner A, Weisenberger D, Ehemann V, Reifenberger G, Lichter P. 1998. Centrosome amplification as a possible mechanism for numerical chromosome aberrations in cerebral primitive neuroectodermal tumors with TP53 mutations. Cytogenet Cell Genet 83:266-269. (Pubitemid 29112761)
64. Williams BR, Prabhu VR, Hunter KE, Glazier CM, Whittaker CA, Housman DE, Amon A. 2008. Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science 322:703-709.
65. Wu G, Nomoto S, Hoque MO, Dracheva T, Osada M, Lee CC, Dong SM, Guo Z, Benoit N, Cohen Y, Rechthand P, Califano J, Moon CS, Ratovitski E, Jen J, Sidransky D, Trink B. 2003. DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res 63:2351-2357. (Pubitemid 36605166)
66. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. 2010. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:1114-1117.
67. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. 1992. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948.
68. Zenz T, Krober A, Scherer K, Habe S, Buhler A, Benner A, Denzel T, Winkler D, Edelmann J, Schwanen C, Dohner H, Stilgenbauer S. 2008. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-term follow-up. Blood 112:3322-3329.
69. Zha S, Boboila C, Alt FW. 2009. Mre11: Roles in DNA repair beyond homologous recombination. Nat Struct Mol Biol 16:798-800.
70. Zhu C, Mills KD, Ferguson DO, Lee C, Manis J, Fleming J, Gao Y, Morton CC, Alt FW. 2002. Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell 109:811-821. (Pubitemid 34785997)